Patent Grant
11077193
The present application is a U.S. National Phase of International Patent Application Serial No. PCT/CN2016/079571, entitled “NERVE GROWTH FACTOR COMPOSITION AND POWDER INJECTION,” filed on Apr. 18, 2016. International Patent Application Serial No. PCT/CN2016/079571 claims priority to Chinese Patent Application No. 201510189156.3, filed on Apr. 21, 2015. The entire contents of each of the above-cited applications are hereby incorporated by reference for all purposes.
The present invention relates to a nerve growth factor composition and an injection powder, and belongs to the field of pharmaceutical biology.
Nerve growth factor (NGF) is a nerve cell growth regulator with the double biological functions of neuronal nutrition and neurite growth promotion, and it has an important regulatory effect on the development, differentiation, growth, regeneration and functional property expression of the central and peripheral neurons. NGF contains three subunits, α, β, γ, wherein the β subunit is an active region, formed by two single chains composed of 118 amino acids by a non-covalent bond. In 1953, the Italian scientist Levi-Montalcini discovered NGF and won the Nobel Prize. At present, there are a number of NGF products which appear on the market all over the world, and they are clinically used mainly for the treatment of neurological dysplasia, including amblyopia, neuroma, various nerve injury and neurological diseases and other diseases.
NGF is similar to other proteins; since the protein has a short half life, the spatial conformation of the protein easily changes and thus results in protein denaturation when exposed to extreme temperature and humidity conditions, or by influenced by physical and chemical factors; the denaturated protein will lose its original biological activity; in addition, because the protein often tends to adhere to a solid surface, in the container filling process, part of the protein will adhere to the inner wall of the container, resulting in the loss of active ingredients. In order to ensure its biological activity, there is a need to add a stabilizer to prevent the loss of the biological activity.
Generally, albumin is widely used in various biological products as an excellent stabilizer and as a cake forming agent. However, since albumin is mainly derived from human blood, placental blood, and the blood may carry some of the unknown components which are not easy to be detected, the NGF composition as a non-sterile preparation which is sterilized, may easily be contaminated; at the same time, the long-term and wide applications of albumin are also susceptible to blood supply constraints and production costs; again, in the determination of the contents of the intermediates and preparation of finished product, albumin may interfere with a relatively small amount of NGF and thus affect the product quality management. Therefore, in order to avoid the above problems, it is necessary to find a stable albumin-free NGF composition.
It is an object of the present invention to provide a nerve growth factor composition and an injection powder which not only protect mouse-derived nerve growth factor (mNGF) but also can ensure the good stability of human-derived nerve growth factor (hNGF) and recombinant human nerve growth factor (rhNGF) in the preparation, transportation and storage processes, and have better clinical medication safety and quality controllability.
The present invention provides a nerve growth factor composition comprising the following components:
The addition of a stabilizer in the above nerve growth factor composition avoids or reduces the aggregation and depolymerization of proteins caused in the preparation or storage process, and the term “stabilizer” refers to a substance which prevents the active ingredient from aggregating or depolymerizing in an aqueous solution, and in addition to the function of stability, the stabilizer can also be used as a supporting agent to improve the product formability, with other functions being not excluded;
In the above nerve growth factor composition, preferably, the mass-volume concentration of said disaccharide stabilizer is 30 mg/mL-70 mg/mL, and more preferably, the mass-volume concentration of said disaccharide stabilizer is 30 mg/mL;
In the above nerve growth factor composition, said disaccharide stabilizer may be at least one of maltose, trehalose, sucrose and lactose;
In the above nerve growth factor composition, preferably, the mass-volume concentration of said amino acid stabilizer is 2 mg/mL-10 mg/mL, and more preferably, the mass-volume concentration of said amino acid stabilizer is 3 mg/mL-10 mg/mL, and still preferably, the mass-volume concentration of said amino acid stabilizer is 3 mg/mL, 10 mg/mL.
In the above nerve growth factor composition, said amino acid stabilizer may be at least one of alanine, glycine, arginine, glutamic acid, histidine and isoleucine.
In the above nerve growth factor composition, said disaccharide stabilizer and said amino acid stabilizer may specifically be any one of the following 1) to 8):
sucrose and histidine, 2) sucrose and glycine, 3) sucrose, glycine and histidine, 4) lactose and glycine, 5) lactose, sucrose and isoleucine, 6) trehalose, arginine and histidine, 7) maltose, glycine and histidine, 8) maltose, alanine, arginine and glutamic acid.
In the above nerve growth factor composition, since the protein has a high tendency to interact with a surface, it is susceptible to adsorption and/or denaturation at a gas-liquid, bottle-liquid interface, which is inversely proportional to the protein concentration, and leads to the formation of soluble and insoluble protein aggregates, or the loss of protein in the solution by adsorption to the interface. The addition of the surfactant can prevent the adsorption and/or denaturation initiated by the solution surface interactions such that the adsorption and/or denaturation caused by the surface is minimized. This is because the surfactant is an amphoteric molecule that can compete with the protein at the interface position, and the hydrophobic portion of the surfactant molecule occupies the interface position (e.g., gas-liquid), while the hydrophilic portion of the molecule remains directed to the solvent bulk; at a sufficient concentration (usually around the critical micelle concentration of the surfactant), the surface layer of the surfactant molecule acts to prevent the adsorption of protein molecules at the interface;
in the above nerve growth factor composition, preferably, the mass-volume concentration of said surfactant is 0.1 mg/mL-0.5 mg/mL, and more preferably, the mass-volume concentration of said surfactant is 0.2 mg/mL-0.5 mg/mL, and still preferably, the mass-volume concentration of said surfactant is 0.2 mg/mL, 0.5 mg/mL;
in the above nerve growth factor composition, said surfactant may be a nonionic surfactant, and preferably said nonionic surfactant may be at least one of poloxamer, polysorbate and 15-polyethleneglycol hydroxystearate (abbreviated as HS 15, the same below), and in particular may be any one of poloxamer, polysorbate and HS 15.
In the above nerve growth factor composition, the addition of said supporting agent can improve the appearance of the finished product and ensure that the product has good formability after lyophilization;
in the above nerve growth factor composition, preferably, the mass-volume concentration of said supporting agent is 20-50 mg/mL, and more preferably, the mass-volume concentration of said supporting agent is 20 mg/mL, 50 mg/mL;
in the above nerve growth factor composition, said supporting agent may be any of mannitol, dextrin and dextran.
In the above nerve growth factor composition, in order to ensure that the composition has the greatest biological activity, it is generally necessary to control an optimum pH range. The optimum pH range for this stability needs to be determined at the time of formulation screening, usually using an influencing factor test (illumination, high temperature, high humidity), accelerated and long-term stability tests and other methods. After the determination of the formulation, the composition in the production and storage processes must be maintained at its optimum pH range. Since the pH buffer has good buffering capacity, the relative stability of the product pH can be maintained in a certain range; therefore, a buffer is often added for the control of pH value in the formulation;
in the above nerve growth factor composition, the molar concentration of said pH buffer is 10 mM-50 mM, preferably, the molar concentration of said pH buffer is 20 mM-25 mM, and more preferably, the molar concentration of said pH buffer is 20 mM, 25 mM;
in the above nerve growth factor composition, preferably, said nerve growth factor composition is maintained at pH value of 6.80-7.00, more preferably, said nerve growth factor composition is maintained at pH value of 6.86-6.91, and still preferably, said nerve growth factor is maintained at pH value of 6.86, specifically 6.80, 6.82, 6.83, 6.85, 6.86, 6.87, 6.91, 6.92 or 7.00;
in the above nerve growth factor composition, the pH buffer is at least one of a phosphate, a citrate, an acetate, a histidine hydrochloride and an arginine hydrochloride, and may specifically be 1) a phosphate, 2) a citrate, 3) an acetate, 4) a histidine hydrochloride, or 5) a histidine hydrochloride and an arginine hydrochloride, wherein the molar ratio of the histidine hydrochloride to the arginine hydrochloride in the 5) may be 12:13.
In the above nerve growth factor composition, said water is water for injection.
In the above nerve growth factor composition, said nerve growth factor is a nerve cell growth regulator with the double biological functions of neuronal nutrition and neurite growth promotion, and it has an important regulatory effect on the development, differentiation, growth, regeneration and functional property expression of the central and peripheral neurons;
in the above nerve growth factor composition, preferably, the mass-volume concentration of said nerve growth factor is 40 μg/mL-60 μg/mL, more preferably the mass-volume concentration of said nerve growth factor is 50 μg/mL;
in the above nerve growth factor composition, said nerve growth factor is a mouse-derived nerve growth factor, a human-derived nerve growth factor, or a recombinant human nerve growth factor.
In the above nerve growth factor composition, the concentration of each component may be any one of the following 1) to 17):
1) the nerve growth factor: 40 μg/mL-80 μg/mL, the disaccharide stabilizer: 10 mg/mL-40 mg/mL, the amino acid stabilizer: 0 mg/mL-6 mg/mL, the surfactant: 0.01 mg/mL-0.2 mg/mL, the supporting agent: 10 mg/mL-30 mg/mL, the pH buffer: 10 mM-25 mM;
2) the nerve growth factor: 60 μg/mL-100 μg/mL, the disaccharide stabilizer: 40 mg/mL-80 mg/mL, the amino acid stabilizer: 6 mg/mL-30 mg/mL, the surfactant: 0.2 mg/mL-1 mg/mL, the supporting agent: 30 mg/mL-50 mg/mL, the pH buffer: 25 mM-50 mM;
3) the nerve growth factor: 10 μg/mL-50 μg/mL, the disaccharide stabilizer: 30 mg/mL-50 mg/mL, the amino acid stabilizer: 2 mg/mL-10 mg/mL, the surfactant: 0.05 mg/mL-0.4 mg/mL, the supporting agent: 20 mg/mL-40 mg/mL, the pH buffer: 20 mM-30 mM;
4) the nerve growth factor: 10 μg/mL-50 μg/mL, the disaccharide stabilizer: 35 mg/mL-70 mg/mL, the amino acid stabilizer: 3 mg/mL-13 mg/mL, the surfactant: 0.1 mg/mL-0.5 mg/mL, the supporting agent: 20 mg/mL-40 mg/mL, the pH buffer: 20 mM-30 mM;
5) the nerve growth factor: 10 μg/mL-50 μg/mL, the disaccharide stabilizer: 35 mg/mL-70 mg/mL, the amino acid stabilizer: 4 mg/mL-14 mg/mL, the surfactant: 0.1 mg/mL-0.5 mg/mL, the supporting agent: 20 mg/mL-40 mg/mL, the pH buffer: 20 mM-30 mM;
6) the nerve growth factor: 40 μg/mL-60 μg/mL, the disaccharide stabilizer: 30 mg/mL-70 mg/mL, the amino acid stabilizer: 0 mg/mL-10 mg/mL, the surfactant: 0.2 mg/mL-0.5 mg/mL, the supporting agent: 20 mg/mL-50 mg/mL, the pH buffer: 20 mM-25 mM;
7) the nerve growth factor: 40 μg/mL-60 μg/mL, the disaccharide stabilizer: 30 mg/mL-70 mg/mL, the amino acid stabilizer: 3 mg/mL-10 mg/mL, the surfactant: 0.2 mg/mL-0.5 mg/mL, the supporting agent: 20 mg/mL to 50 mg/mL, the pH buffer: 20 mM to 25 mM;
8) the nerve growth factor: 10 μg/mL, the disaccharide stabilizer: 10 mg/mL, the amino acid stabilizer: 0 mg/mL, the surfactant: 0.01 mg/mL, the supporting agent: 10 mg/mL, the pH buffer: 10 mM;
9) the nerve growth factor: 40 μg/mL, the disaccharide stabilizer: 30 mg/mL, the amino acid stabilizer: 2 mg/mL, the surfactant: 0.05 mg/mL, the supporting agent: 20 mg/mL, the pH buffer: 20 mM;
10) the nerve growth factor: 50 μg/mL, the disaccharide stabilizer: 35 mg/mL, the amino acid stabilizer: 3 mg/mL, the surfactant: 0.1 mg/mL, the supporting agent: 30 mg/mL, the pH buffer: 25 mM;
11) the nerve growth factor: 60 μg/mL, the disaccharide stabilizer: 40 mg/mL, the amino acid stabilizer: 4 mg/mL, the surfactant: 0.2 mg/mL, the supporting agent: 40 mg/mL, the pH buffer: 30 mM;
12) the nerve growth factor: 80 μg/mL, the disaccharide stabilizer: 50 mg/mL, the amino acid stabilizer: 6 mg/mL, the surfactant: 0.4 mg/mL, the supporting agent: 50 mg/mL, the pH buffer: 50 mM;
13) the nerve growth factor: 100 μg/mL, the disaccharide stabilizer: 70 mg/mL, the amino acid stabilizer: 10 mg/mL, the surfactant: 0.5 mg/mL, the supporting agent: 50 mg/mL, the pH buffer: 50 mM;
14) the nerve growth factor: 100 μg/mL, the disaccharide stabilizer: 80 mg/mL, the amino acid stabilizer: 13 mg/mL, the surfactant: 1 mg/mL, the supporting agent: 50 mg/mL, the pH buffer: 50 mM;
15) the nerve growth factor: 100 μg/mL, the disaccharide stabilizer: 80 mg/mL, the amino acid stabilizer: 14 mg/mL, the surfactant: 1 μg/mL, the supporting agent: 50 mg/mL, the pH buffer: 50 mM;
16) the nerve growth factor: 100 μg/mL, the disaccharide stabilizer: 80 mg/mL, the amino acid stabilizer: 30 mg/mL, the surfactant: 1 mg/mL, the supporting agent: 50 mg/mL, the pH buffer: 50 mM;
17) the nerve growth factor: 50 μg/mL, the disaccharide stabilizer: 30 mg/mL, the amino acid stabilizer: 3 mg/mL, the surfactant: 0.2 mg/mL, the supporting agent: 50 mg/mL, the pH buffer: 25 mM;
18) the nerve growth factor: 50 μg/mL, the disaccharide stabilizer: 30 mg/mL, the amino acid stabilizer: 10 mg/mL, the surfactant: 0.5 mg/mL, the supporting agent: 20 mg/mL, the pH buffer: 20 mM.
The present invention further provides a method for preparing the above nerve growth factor composition injection powder, wherein the above nerve growth factor composition is lyophilized to obtain the nerve growth factor composition injection powder.
It is another object of the present invention to provide a nerve growth factor composition injection powder prepared by the above method, for injection administration.
In the above nerve growth factor composition injection powders, the water content of the injection powders may be 1.2%-3.0%, specifically 1.3%, 1.7%, 1.9%, 2.2%, 2.3%, 2.4%, 2.5%, 2.7% or 2.8%; the pH value of the injection powders may be 6.80-7.20, specifically 6.80, 6.82, 6.83, 6.85, 6.92, 6.93, 6.95, 7.05, 7.10, 7.10 or 7.20.
The use of the above nerve growth factor compositions in the treatment of nerve injury or the preparation of a medicament for the treatment of nerve injury is also within the scope of the present invention. Said nerve growth factor composition may specifically be a nerve growth factor composition injection powder. The nerve injury may be an optic nerve injury, and the cause of the injury may be a first injury, a car accident, a physical hit injury or an eye explosive injury.
The present invention further provides a method of treating nerve injury comprising the step of: administering an effective amount of a nerve growth factor composition to a patient with the nerve injury. Said nerve growth factor composition may specifically be a nerve growth factor composition injection powder. The administration may specifically be intramuscular injection. The nerve injury may be an optic nerve injury, and the cause of the injury may be a first injury, a car accident, a physical hit injury or an eye explosive injury.
In order to provide a better understanding of the technical solution of the present invention to those skilled in the art, the present invention will be described in further detail with reference to examples and test examples, but these examples are not to be construed as limiting the present invention.
The experimental methods used in the following Examples are conventional methods unless otherwise specified.
The materials, reagents and the like used in the following Examples are commercially available, unless otherwise specified.
The mNGF and hNGF stock solutions used in the following Examples are supplied by the Staidson (Beijing) Biopharmaceuticals Co., Ltd., the rhNGF stock solution is supplied by the Sino Biological Inc., and the rest of the excipients are all injection grade unless otherwise specified.
The unit of concentration of the surfactant in the following Examples is expressed in %, such as 0.1% for 1 mg/mL.
In order to find a substitute for albumin as a stabilizer for NGF, in the present invention, a large number of exploratory experiments have been carried out, in which maltose, trehalose, sucrose, lactose, alanine, glycine, arginine, glutamic acid, histidine, isoleucine as a stabilizer for this product and polysorbate-20 (abbreviated as TW-20, the same below), polysorbate-80 (abbreviated as TW-80, the same below), poloxamer 188 (abbreviated as F68, the same below), HS 15 as a surfactant are used to prepare a variety of NGF compositions and injection powders, and the moisture, pH, osmotic pressure, content and activity of the finished products are determined.
The NGF composition and the injection powder are prepared as follows:
a formulation amount of a citrate is weighed according to the formulation composition in Table 1, an appropriate amount of water for injection is added and stirred to complete dissolution, then formulation amounts of trehalose, mannitol and F68 are added and stirred to complete dissolution, a hNGF stock solution is added, the pH is adjusted to pH 6.85 as shown in Table 1 with NaOH or citric acid, water for injection is added to the volume of the scale, after having been mixed uniformly, the mixture is filtered through a 0.22 μm microfiltration membrane into a sterile container to prepare a composition having an NGF concentration of about 80 μg/mL.
The above composition is subpackaged into a borosilicate glass injection bottle at 0.63±0.03 mL/bottle and lyophilized, to prepare a sterile powder for hNGF injection, i.e., a hNGF injection powder.
The NGF composition and the injection powder are prepared as follows:
a formulation amount of a phosphate is weighed according to the formulation composition in Table 1, an appropriate amount of water for injection is added and stirred to complete dissolution, then formulation amounts of sucrose, glycine, histidine and dextran are added and stirred to complete dissolution; since the TW-20 in the formulation is in a spherical aggregate state in the water for injection and is not easily mixed uniformly, TW-20 is firstly dissolved in hot water for injection (40° C.-80° C.) to formulate into an 1% aqueous solution, and after having been cooled to room temperature, it is added into the above solution in an amount converted from the formulation amount, and mixed uniformly in the present invention; finally, a rhNGF stock solution is added, the pH is adjusted to pH 7.00 as shown in Table 1 with NaOH or phosphoric acid, and water for injection is add to the volume of the scale, after having been mixed uniformly, the mixture is filtered through a 0.22 μm microfiltration membrane into a sterile container to prepare a composition having an NGF concentration of about 50 μg/mL.
The above composition is subpackaged into a borosilicate glass injection bottle at 0.63±0.03 mL/bottle and lyophilized, to prepare a sterile powder for rhNGF injection, i.e., a rhNGF injection powder.
The NGF composition and the injection powder are prepared as follows:
a formulation amount of an acetate is weighed according to the formulation composition in Table 1, an appropriate amount of water for injection is added and stirred to complete dissolution, then formulation amounts of maltose, alanine, arginine, glutamic acid and mannitol are added and stirred to complete dissolution; since the HS 15 in the formulation is in a spherical aggregate state in the water for injection and is not easily mixed uniformly, HS 15 is firstly dissolved in hot water for injection (40° C.-80° C.) to formulate into an 1% aqueous solution, and after having been cooled to room temperature, it is added into the above solution in an amount converted from the formulation amount, and mixed uniformly in the present invention; finally, a hNGF stock solution is added, the pH is adjusted to pH 6.92 as shown in Table 1 with NaOH or acetic acid, and water for injection is add to the volume of the scale, after having been mixed uniformly, the mixture is filtered through a 0.22 μm microfiltration membrane into a sterile container to prepare a composition having an NGF concentration of about 40 μg/mL.
The above composition is subpackaged into a borosilicate glass injection bottle at 0.63±0.03 mL/bottle and lyophilized, to prepare a sterile powder for hNGF injection, i.e., a hNGF injection powder.
The NGF composition and the injection powder are prepared as follows:
a formulation amount of a histidine hydrochloride is weighed according to the formulation composition in Table 1, an appropriate amount of water for injection is added and stirred to complete dissolution, then formulation amounts of sucrose, histidine and mannitol are added and stirred to complete dissolution; since the TW-20 in the formulation is in a spherical aggregate state in the water for injection and is not easily mixed uniformly, TW-20 is firstly dissolved in hot water for injection (40° C.-80° C.) to formulate into an 1% aqueous solution, and after having been cooled to room temperature, it is added into the above solution in an amount converted from the formulation amount, and mixed uniformly in the present invention; finally, a hNGF stock solution is added, the pH is adjusted to pH 6.87 as shown in Table 1 with HCl or L-histidine, and water for injection is add to the volume of the scale, after having been mixed uniformly, the mixture is filtered through a 0.22 μm microfiltration membrane into a sterile container to prepare a composition having an NGF concentration of about 60 μg/mL.
The above composition is subpackaged into a borosilicate glass injection bottle at 0.63±0.03 mL/bottle and lyophilized, to prepare a sterile powder for hNGF injection, i.e., a hNGF injection powder.
The NGF composition and the injection powder are prepared as follows:
a formulation amount of a citrate is weighed according to the formulation composition in Table 1, an appropriate amount of water for injection is added and stirred to complete dissolution, then formulation amounts of trehalose, sucrose mannitol are added and stirred to complete dissolution; since the TW-80 in the formulation is in a spherical aggregate state in the water for injection and is not easily mixed uniformly, TW-80 is firstly dissolved in hot water for injection (40° C.-80° C.) to formulate into an 1% aqueous solution, and after having been cooled to room temperature, it is added into the above solution in an amount converted from the formulation amount, and mixed uniformly in the present invention; finally, a mNGF stock solution is added, the pH is adjusted to pH 6.82 as shown in Table 1 with NaOH or citric acid, and water for injection is add to the volume of the scale, after having been mixed uniformly, the mixture is filtered through a 0.22 μm microfiltration membrane into a sterile container to prepare a composition having an NGF concentration of about 60 μg/mL.
The above composition is subpackaged into a borosilicate glass injection bottle at 0.63±0.03 mL/bottle and lyophilized, to prepare a sterile powder for mNGF injection, i.e., a mNGF injection powder.
The NGF composition and the injection powder are prepared as follows:
a formulation amount of a phosphate is weighed according to the formulation composition in Table 1, an appropriate amount of water for injection is added and stirred to complete dissolution, then formulation amounts of sucrose, glycine and mannitol are added and stirred to complete dissolution; since the TW-80 in the formulation is in a spherical aggregate state in the water for injection and is not easily mixed uniformly, TW-80 is firstly dissolved in hot water for injection (40° C.-80° C.) to formulate into an 1% aqueous solution, and after having been cooled to room temperature, it is added into the above solution in an amount converted from the formulation amount, and mixed uniformly in the present invention; finally, a hNGF stock solution is added, the pH is adjusted to pH 6.91 as shown in Table 1 with NaOH or phosphoric acid, and water for injection is add to the volume of the scale, after having been mixed uniformly, the mixture is filtered through a 0.22 μm microfiltration membrane into a sterile container to prepare a composition having an NGF concentration of about 50 μg/mL.
The above composition is subpackaged into a borosilicate glass injection bottle at 0.63±0.03 mL/bottle and lyophilized, to prepare a sterile powder for hNGF injection, i.e., a hNGF injection powder.
The NGF composition and the injection powder are prepared as follows:
a formulation amount of a histidine hydrochloride is weighed according to the formulation composition in Table 1, an appropriate amount of water for injection is added and stirred to complete dissolution, then formulation amounts of maltose, glycine, histidine and dextrin are added and stirred to complete dissolution; since the TW-80 in the formulation is in a spherical aggregate state in the water for injection and is not easily mixed uniformly, TW-80 is firstly dissolved in hot water for injection (40° C.-80° C.) to formulate into an 1% aqueous solution, and after having been cooled to room temperature, it is added into the above solution in an amount converted from the formulation amount, and mixed uniformly in the present invention; finally, a rhNGF stock solution is added, the pH is adjusted to pH 6.80 as shown in Table 1 with HCl or L-histidine, and water for injection is add to the volume of the scale, after having been mixed uniformly, the mixture is filtered through a 0.22 μm microfiltration membrane into a sterile container to prepare a composition having an NGF concentration of about 100 μg/mL.
The above composition is subpackaged into a borosilicate glass injection bottle at 0.63±0.03 mL/bottle and lyophilized, to prepare a sterile powder for rhNGF injection, i.e., a rhNGF injection powder.
The NGF composition and the injection powder are prepared as follows:
a formulation amount of a citrate is weighed according to the formulation composition in Table 1, an appropriate amount of water for injection is added and stirred to complete dissolution, then formulation amounts of trehalose, and mannitol are added and stirred to complete dissolution; since the HS 15 in the formulation is in a spherical aggregate state in the water for injection and is not easily mixed uniformly, HS 15 is firstly dissolved in hot water for injection (40° C.-80° C.) to formulate into an 1% aqueous solution, and after having been cooled to room temperature, it is added into the above solution in an amount converted from the formulation amount, and mixed uniformly in the present invention; finally, a hNGF stock solution is added, the pH is adjusted to pH 6.86 as shown in Table 1 with NaOH or citric acid, and water for injection is add to the volume of the scale, after having been mixed uniformly, the mixture is filtered through a 0.22 μm microfiltration membrane into a sterile container to prepare a composition having an NGF concentration of about 40 μg/mL.
The above composition is subpackaged into a borosilicate glass injection bottle at 0.63±0.03 mL/bottle and lyophilized, to prepare a sterile powder for hNGF injection, i.e., a hNGF injection powder.
The NGF composition and the injection powder are prepared as follows:
a formulation amount of a phosphate is weighed according to the formulation composition in Table 1, an appropriate amount of water for injection is added and stirred to complete dissolution, then formulation amounts of lactose, glycine and mannitol are added and stirred to complete dissolution; since the TW-20 in the formulation is in a spherical aggregate state in the water for injection and is not easily mixed uniformly, TW-20 is firstly dissolved in hot water for injection (40° C.-80° C.) to formulate into an 1% aqueous solution, and after having been cooled to room temperature, it is added into the above solution in an amount converted from the formulation amount, and mixed uniformly in the present invention; finally, a hNGF stock solution is added, the pH is adjusted to pH 6.86 as shown in Table 1 with NaOH or phosphoric acid, and water for injection is add to the volume of the scale, after having been mixed uniformly, the mixture is filtered through a 0.22 μm microfiltration membrane into a sterile container to prepare a composition having an NGF concentration of about 50 μg/mL.
The above composition is subpackaged into a borosilicate glass injection bottle at 0.63±0.03 mL/bottle and lyophilized, to prepare a sterile powder for hNGF injection, i.e., a hNGF injection powder.
The NGF composition and the injection powder are prepared as follows:
formulation amounts of a histidine hydrochloride and an arginine hydrochloride are weighed according to the formulation composition in Table 1, an appropriate amount of water for injection is added and stirred to complete dissolution, then formulation amounts of trehalose, arginine, histidine and mannitol are added and stirred to complete dissolution; since the TW-20 in the formulation is in a spherical aggregate state in the water for injection and is not easily mixed uniformly, TW-20 is firstly dissolved in hot water for injection (40° C.-80° C.) to formulate into an 1% aqueous solution, and after having been cooled to room temperature, it is added into the above solution in an amount converted from the formulation amount, and mixed uniformly in the present invention; finally, a rhNGF stock solution is added, the pH is adjusted to pH 6.83 as shown in Table 1 with HCl or L-histidine or L-arginine, and water for injection is add to the volume of the scale, after having been mixed uniformly, the mixture is filtered through a 0.22 μm microfiltration membrane into a sterile container to prepare a composition having an NGF concentration of about 60 μg/mL.
The above composition is subpackaged into a borosilicate glass injection bottle at 0.63±0.03 mL/bottle and lyophilized, to prepare a sterile powder for rhNGF injection, i.e., a rhNGF injection powder.
The NGF composition and the injection powder are prepared as follows:
a formulation amount of a phosphate is weighed according to the formulation composition in Table 1, an appropriate amount of water for injection is added and stirred to complete dissolution, then formulation amounts of lactose, sucrose, isoleucine, mannitol and F68 are added and stirred to complete dissolution, a mNGF stock solution is added, the pH is adjusted to pH 6.85 as shown in Table 1 with NaOH or phosphoric acid, water for injection is added to the volume of the scale, after having been mixed uniformly, the mixture is filtered through a 0.22 μm microfiltration membrane into a sterile container to prepare a composition having an NGF concentration of about 10 μg/mL.
The above composition is subpackaged into a borosilicate glass injection bottle at 0.63±0.03 mL/bottle and lyophilized, to prepare a sterile powder for mNGF injection, i.e., a mNGF injection powder.
(1) Test of Appearance, Moisture, Osmotic Pressure, pH, Content and Activity
The NGF composition injection powders prepared in Examples 1-11 and a reference preparation (mouse nerve growth factor for injection, trade name: Sutaisheng, manufactured by the Staidson (Beijing) Biopharmaceuticals Co., Ltd.) are observed for the appearances, respectively, and their moistures, osmotic pressures, pHs, contents and activities are determined. The method of determining the NGF content is carried out according to the method described in Example 1 in Patent No. 200510130348.3, entitled “Method for Determining the Content of Nerve Growth Factor”. The activity test method is determined by a cell method, and the detailed method of operation is carried out according to the method of Example 1 in Patent Publication No. CN 103376248A, entitled “Method for Quantitative Determination of Nerve Growth Factor Activity”. The experimental results are shown in Table 2.
As can be seen from Table 2, the indexes of the NGF composition injection powders prepared in the present invention all meet the quality standard requirements.
(2) Stable pH Range Screening
According to the formulation composition of Example 2, 3 NGF compositions are formulated, wherein the total amount of phosphate is kept constant and the amounts of the NaH2PO4.H2O and Na2HPO4 are adjusted so that the pH values of the NGF compositions are 6.0, 6.8 and 7.4, respectively, then filled into penicillin bottles, respectively, and lyophilized to prepare sterile injection powder. Samples are taken, and an appropriate amount of sterile water for injection is added to formulate into solutions. Under room temperature condition, the solutions are observed for the appearance and determined for the pH value, the content and the activity are measured at 0, 4, 8, 12 and 24 hours, respectively. The results are shown in the following table.
It can be seen from the above table data that after the three NGF compositions with different pH values are placed at room temperature for 24 h, the indexes all have no significant changes than at 0 h, all meet the quality standard requirements, indicating that under room temperature condition, the sample solutions can remain stable for 24 h in a range of pH 6.0-7.4, preferably at pH 6.8.
(3) Stability Test
A. Accelerated Stability Test
According to the requirements of “Technical Guidelines for Research on Stability of Biological Products”, the samples of the reference preparation (Sutaisheng) and the subpackaged NGF composition injection powders prepared in the Examples are examined for an accelerated stability for 0-6 months under conditions of 25° C., RH 60±10%. The samples are observed for the appearances, and determined for the moistures, osmotic pressures, pH values, contents and activities. The results are shown in Table 4 and
As can be seen from
As can be seen from
B. Long-Term Stability Test
According to the requirements of “Technical Guidelines for Research on Stability of Biological Products”, the samples of the reference preparation (Sutaisheng) and the subpackaged NGF injection powders prepared in the Examples 4, 6, 8 and 9 are examined for a long-term stability for 0-12 months under condition of 6±2° C. The samples are observed for the appearances, and determined for the moistures, osmotic pressures, pH values, contents and activities. The results are shown in Table 5, and
As can be seen from
As can be seen from
(4) Clinical Evaluation
A total of 271 patients with optic nerve injury are subjected to a 12-weeks clinical trial by the multicenter non-randomized controlled clinical study design; all the subjects are 14 years or older, and are able to communicate well with the investigators, understand and comply with clinical trial requirements, and sign an informed consent.
Subject condition: 14 years or older.
Gender: male or female.
Subject source: 409 patients with optic nerve injury caused by various causes from various ophthalmic research units being enrolled.
Injury cause: 136 cases of first injury (136 eyes), 152 cases of car accident (152 eyes), 73 cases of physical hit injury (73 eyes), 49 cases of eye explosive injury (49 eyes). All cases are not accompanied by eyeball rupture and damage caused by the optic nerve compression due to orbital fractures.
Treatment method: the treatment group is injected with the reference preparation and the NGF compositions of the present invention by intramuscular injection (water for injection) once a day with each 30 μg, and all cases are administered continuously for 12 weeks. The placebo group is treated with a negative control (with no active ingredient, and the remaining excipients being the same to those in the NGF compositions).
The treatment group comprises 271 cases (271 eyes), with age of 18 to 63 years, and the average age of 34.2 years; 189 males (189 eyes), 82 females (82 eyes); 147 eyes in the right eye, 124 eyes in the left eye. The placebo group comprises 138 patients (138 eyes), with age of 13-55 years, and the average age of 33.9 years, 96 males (96 eyes), 42 females (42 eyes), 45 eyes in the right eye and 93 eyes in the left eye.
Grouping design: grouping is shown in the following table:
Clinical common adverse reaction evaluation: the placebo group, the reference preparation group and the NGF composition group are administered, respectively, and observed for the symptom and incidence of the adverse reactions in each group, and the results are shown in the following table.
#indicates that there is a significant difference compared with the reference preparation group (P < 0.05).
It can be seen from the above table that, compared with the placebo group, the main adverse reactions of the NGF compositions prepared in the present invention are local pain, urticaria and dizziness, and compared with the reference preparation group, the NGF compositions prepared in the present invention can significantly alleviate the adverse reactions, such as local pain, urticaria, dizziness, etc.
Clinical efficacy: the placebo group, the reference preparation group and the NGF composition group are administered, respectively, and observed for the clinical efficacy in each group. The results are shown in the following table.
The clinical efficacy in the above table is evaluated using the following clinical efficacy evaluation criteria:
{circle around (1)} Recovery: the vision recovers to 1.0 or more, and dark spots in the central visual field disappear;
{circle around (2)} Effective: the vision increases by 4 lines or more, dark spots in the central visual field reduce or the absolute dark spots become relative dark spots;
{circle around (3)} Alleviated: the vision increases by 2 lines or more, and there is no change in visual field;
{circle around (4)} Ineffective: the vision and visual field are the same as before the treatment, or decline.
It can be seen from the above table that, compared with the placebo group, the NGF compositions and the injection powders thereof of the present invention can be effective in treating optic nerve injury caused by various causes, have the comprehensive efficiency of the treatment of optic nerve injury that is superior to that of the reference preparation group, can significantly reduce the incidence of the adverse reactions, and have good clinical therapeutic effect.
While the present invention has been described in detail by way of general description, particular embodiments and examples, various modifications and improvements may be made by those skilled in the art on the basis of the present invention without departing from the spirit of the invention and such modifications or improvements are all within the scope according to the present invention.
The nerve growth factor composition injection powders prepared in the present invention retain good stability in preparation, transportation and storage processes: (1) in the preparation process: after the nerve growth factor composition injection powders prepared in the present invention are placed at room temperature for 24 hours, the content and activity of the NGF therein have no significant change; (2) compared with the reference preparation, in the conventional (6±2° C.) transportation and storage processes, the NGF composition injection powders of the present invention has an effective content reduction of only 2.0%-6.3%, preferably 2.0%-3.0%, and an activity reduction of only 3.4%-10.9%, after being placed for 12 months, thereby having the excellent stability.
The nerve growth factor composition injection powders prepared in the present invention can significantly reduce the incidence of the adverse reactions in the clinical trial, have good clinical therapeutic effect, and have better clinical medication safety and quality controllability as compared with the existing reference preparation.
The present invention has the following beneficial effects:
(1) the nerve growth factor compositions and the injection powders of the present invention can avoid the potential risk resulting from the virus or other unknown components carried in albumin by using a disaccharide or a combination of a disaccharide and an amino acid instead of albumin as a stabilizer.
(2) the nerve growth factor composition injection powders of the present invention not only have protective effect on mouse-derived nerve growth factor (mNGF), but also can ensure the good stability of the human-derived nerve growth factor (hNGF) and the recombinant human nerve growth factor (rhNGF) in the preparation, transportation and storage processes, and have better clinical medication safety and quality controllability.
(3) the nerve growth factor compositions and the injection powders of the present invention have definite ingredients, are easily qualitative and quantitative, and the stabilizer used therein has a high purity, a wide source and easy long-term mass production, which facilitate the cost control and the product quality improvement.
| Number | Date | Country | Kind |
|---|---|---|---|
| 201510189156.3 | Apr 2015 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2016/079571 | 4/18/2016 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2016/169454 | 10/27/2016 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 6277828 | Knepp et al. | Aug 2001 | B1 |
| 20030203040 | Cleland | Oct 2003 | A1 |
| Number | Date | Country |
|---|---|---|
| 1552440 | Dec 2004 | CN |
| 1824297 | Aug 2006 | CN |
| 1857718 | Nov 2006 | CN |
| 101461786 | Jun 2009 | CN |
| 101972224 | Feb 2011 | CN |
| 1552440 | Dec 2004 | WO |
| 2007073035 | Jun 2007 | WO |
| Entry |
|---|
| Hadi et al, Natural surfactants, downloaded on Feb. 16, 2019 from <http://irep.iium.edu.my/14524/1/CHAPTER_10_Natural_surfactants_for_pharmaceutical_emulsions.pdf>, pp. 1-18. |
| Paik et al (Am Inst Chem Eng Biotech Prog 28: 1517-1525, 2012). |
| Russ, Intermed Physics Med Biol, 1-3. (Year: 2017). |
| ISA State Intellectual Property Office of the People's Republic of China, International Search Report Issued in Application No. PCT/CN2016/079571, dated Jul. 13, 2016, WIPO, 9 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20180161436 A1 | Jun 2018 | US |
